Name: WU Yingli
Email: wuyingli@shsmu.edu.cn
Tel: 63846590-776916
Research Field:
Deubiquitinating enzymes and targeted therapies
Deubiquitinating enzymes (DUBs) regulate protein degradation, localization and protein interaction by removing ubiquitination modifications of proteins, thereby participating in various biological processes such as DNA damage repair, cell survival, cell cycle, immune response, and angiogenesis. Accumulating evidence show that DUBs are an emerging class of anti-tumor targets. In recent years, our group has focused on DUBs related studies, mainly including: revealing the role and mechanism of DUBs in tumors; identifying the corresponding DUBs of various important oncoproteins or tumor suppressors; and using DUBs as the target to develop its inhibitors or agonists and evaluate their efficacy in vitro and in vitro. The results have been published in Nature communications, Signal transduction & targeted therapy, Science China Life Sciences and other journals. These studies will provide new mechanisms for the occurrence and development of tumors, and provide new targets and drugs for the treatment of tumors.
Personal Introduction:
Yingli Wu, male, Ph.D., doctoral supervisor, professor of Shanghai Jiao Tong University School of Medicine, chief teacher of blood system of basic medical college. He graduated from the Shanghai Institute of Hematology in 2003 and has since worked in the Department of Pathophysiology of Shanghai Jiao Tong University School of Medicine. From 2004 to 2006, he was a postdoctoral researcher at the Saint-Louis Hospital in Paris, France. He has carried out long-term chemical biology research on leukemia, and in recent years, he has paid special attention to the degradation and regulation of tumor-related proteins. He has published more than 100 SCI papers in international academic journals such as Blood, Nature Communications, Signal transduction & targeted therapy, and won 5 invention patents. He has undertaken a number of surface and cultivation projects funded by the Ministry of Biology, Medicine and Chemistry of the National Natural Science Foundation of China, and 3 key basic projects of Shanghai Municipal Science and Technology Commission. As a backbone, he participated in 2 national key basic research program projects.
Scientific Research Projects:
The Role and Mechanism of USP48 in MLL-Rearranged Acute Myeloid Leukemia. NO. 82470152. Start/End: 2025, 01-2028, 12. National Natural Science Foundation of China.
Molecular mechanisms and effects of ML364-induced degradation of MLL fusion proteins. NO. 82170145. Start/End: 2022, 01-2025, 12. National Natural Science Foundation of China.
Publications: (last five years)
Wang Y, Xu J, Bai W, Zhang Z, Ma C, Tan Y, Zhang Z, Liu W, Wu Y, Liu J, Lei H, Xu H, Weng W, Huang M, Feng X, Zhu L, Yang L, Zhu Q, Wu YL. A degradable multi-metal-chelating stealth nanoplatform for dual ferroptosis/cuproptosis-enhanced metalloimmunotherapy in leukemia. J Nanobiotechnology. 2026 Mar 21.
Luo H, Zhu C, Wang Y, Dai Y, Hao P, Cai H, Bai W, Zhang Z, Wan J, Zhang Y, Sun Y, Zhang Z, Wu Y, Zhai Y, Wu W, Lei H, Xu H, He M, Wu Y. USP2 promotes metabolic dysfunction-associated steatotic liver disease progression via stabilization of PPARγ. Cell Death Differ. 2026 Mar;33(3):525-538.
Shan H, Zhang Y, Xiao X, Wu W, Wang Y, Zhu C, Bai W, Zhang Z, Zhai Y, Yang L, Wu Y, Lei H, Xu H, Luo Y, Lu L, Wu Y. USP7 sustains hematopoietic stem cell homeostasis partially via PU.1 stabilization. Int J Biol Sci. 2026 Jan 1;22(2):1036-1052.
Zhang J, Wu W, Wang Y, Zhang Y, Wang Y, Bai W, Zhang Z, Zhu C, Wu Y, Zhang Z, Yang L, Lei H, Xu H, Zhou L, Wu Y *. Targeting USP2 induces degradation of PML-RARα with or without drug-resistant mutations in acute promyelocytic leukemia. Acta Biochimica et Biophysica Sinica，2025 Aug 11. doi: 10.3724/abbs.2025135.
Zhang Y, Shi H, Wang Y, Liu W, Li G, Li D, Wu W, Wu Y, Zhang Z, Ji Y, Zhu C, Bai W, Lei H, Xu H, Zhong H, Han B, Yang L, Liu L, Wang W, Zhao Y, Zhang Y, Wu Y. Noscapine derivative 428 suppresses ferroptosis through targeting GPX4. Redox Biol. 2025 Apr 12;83:103635
Lei H, Xu HZ, Yang L, Wang YY, Zhang YP, Wu YL. USP47 stabilizes YBX1 to promote the progression of acute myeloid leukemia. Oncogene, 2024 Feb;43(7):539-542
Wang YY, Ji YJ, Luo H, Wei W, Wang WW, Xu HZ, Lei H, Wu YL, Yang L, Liu LG, Wu YL. Identification of USP2 as a novel target to induce degradation of KRAS in myeloma cells, Acta Pharmaceutica Sinica B, 2024, 14:5235-5248
Cai H, Wang Y, Zhang J, Wei Z, Yan T, Feng C, Xu Z, Zhou A, Wu Y. Discovery of Novel SIRT1/2 Inhibitors with Effective Cytotoxicity against Human Leukemia Cells. Journal of Chemical Information and Modeling, J Chem Inf Model. 2023 Aug 14;63(15):4780-4790
Liu M, Zhang Y, Wu Y, Jin J, Cao Y, Fang Z, Geng L, Yang L, Yu M, Bu Z, Ji Y, Shan H, Zou Z, Liu L, Wang Y, Zhang Y, Tong Y, Xu H, Lei H, Liu W, Gao F, Wu YL. IKZF1 selectively enhances homologous recombination repair by interacting with CtIP and USP7 in multiple myeloma. International Journal of Biological sciences, 2022, 18(6):2515-2526.
Lei H, Yang L, Xu H, Wang Z, Li X, Liu M, Wu Y. Ubiquitin-specific protease 47 regulates intestinal inflammation through deubiquitination of TRAF6 in epithelial cells, Science China Life Sciences 2022, FEB 25
Ma QX, Zhu WY, Lu XC, Jiang D, Xu F, Li JT, Zhang L, Wu YL, Chen ZJ, Yin M, Huang HY, Lei QY. BCAA-BCKA axis regulates WAT browning through acetylation of PRDM16. Nat Metab. 2022 Jan;4(1):106-122.
Yin H, Jing B, Xu D, Guo W, Sun B, Zhang J, Liao Y, Song H, Wang T, Liu S, Kuang Y, Hu M, Li K, Zhang S, Zhang H, Xu J, Li X, Du J, Wu Y, Wu Y, Wang Q, Yao F, Chin YE, Zhou BP, Deng J. Identification of Active Bronchioalveolar Stem Cells as the Cell of Origin in Lung Adenocarcinoma. Cancer Res. 2022 Mar 15;82(6):1025-1037.
Patent:
Compound 428 in the preparation of drugs for the prevention, control, or treatment of idiopathic pulmonary fibrosis or GPX4 stabilizers. Inventors: Zhang Yongqiang, Zhang Youping, Wu Yingli, Lei Hu, Wang Yingying, Xu Hanzhang, Bai Wenhui, Zhu Chujiao. Patent application number: 2023113603044
Preparation and Application of Sildenafil Derivatives with Anti-leukemic Activity. Inventors: Zhang Yongqiang, Wu Wenxuan, Wu Yingli, Cui Guangwei, Zhang Youping, Yuan Qiyang, Wang Pan. Patent Application Number: 202510597713.9
Lab Members:
| Name |
Title |
Email |
| HU Lei | Senior Research Assistant | hulei@shsmu.edu.cn |
| Hanzhang Xu | Associate professor | smollyxu@126.com |